Wexford Capital’s Eli Lilly LLY Stock Holding History

Wexford Capital’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-388	Closed	-$296K	–	459
2025 Q3	$296K	Buy	+388	New	+$289K	0.04%	137
2024 Q4	–	Sell	-1,871	Closed	-$1.66M	–	230
2024 Q3	$1.66M	Buy	+1,871	New	+$1.68M	0.4%	49
2024 Q1	–	Sell	-5,335	Closed	-$3.11M	–	259
2023 Q4	$3.11M	Sell	5,335 -141	-3%	-$82.3K	0.67%	45
2023 Q3	$2.94M	Buy	+5,476	New	+$2.82M	0.65%	36
2022 Q4	–	Sell	-813	Closed	-$263K	–	162
2022 Q3	$263K	Buy	813 +2	+0.2%	+$634	0.08%	107
2022 Q2	$263	Buy	811 +2	+0.2%	+$600	0.02%	143
2022 Q1	$232	Buy	+809	New	+$208K	0.01%	137
2013 Q3	–	Sell	-21,822	Closed	-$1.07M	–	238
2013 Q2	$1.07M	Buy	+21,822	New	+$1.19M	0.09%	109

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wexford Capital's LLY Position: Q4 2025 in Review

Wexford Capital sold out of Eli Lilly (LLY) in Q4 2025, closing a stake of 388 shares — an estimated $296K sold.

Wexford Capital first reported a position in LLY in Q2 2013 and held it in 8 quarters. The position peaked at $3.11M in Q4 2023. 4,428 funds tracked by Wall St. Rank hold LLY as of Q4 2025.

Wexford Capital reported no remaining Eli Lilly position as of Q4 2025 after selling out during the quarter.
Wexford Capital sold 388 Eli Lilly shares in Q4 2025, an estimated $296K.
Wexford Capital first reported a position in Eli Lilly in Q2 2013 and held it in 8 quarters.
Wexford Capital's Eli Lilly position peaked at $3.11M in Q4 2023.
4,428 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2025.

Based on Wexford Capital's 13F filing for Q4 2025, filed 13 Feb 2026.